Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NP1010KZ | Other Identifier | company internal |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection.
Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276) | Drug | Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed. |
| Measure | Description | Time Frame |
|---|---|---|
| Percent rate of different vaginal infections | Approximately within 6 months after the last patient last visit. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical characteristics of vaginitis after treatment. | Depending on treatment time chosen by the physician, after 7 or 14 days. | |
| Change of microbiological characteristics after treatment | Depending on treatment time chosen by the physician, after 7 or 14 days. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients in primary care setting.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Kazakhstan |
Not provided
| ID | Term |
|---|---|
| D002181 | Candidiasis, Vulvovaginal |
| D016585 | Vaginosis, Bacterial |
| D014247 | Trichomonas Vaginitis |
| ID | Term |
|---|---|
| D002177 | Candidiasis |
| D009181 | Mycoses |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D008795 | Metronidazole |
| D008825 | Miconazole |
| ID | Term |
|---|---|
| D009593 | Nitroimidazoles |
| D009574 | Nitro Compounds |
| D009930 | Organic Chemicals |
| D007093 | Imidazoles |
Not provided
Not provided
Not provided
Not provided
Not provided
| Patient rating of tolerability and treatment results | Depending on treatment time chosen by the physician, after 7 or 14 days. |
| Physician's rating of tolerability and treatment results | Depending on treatment time chosen by the physician, after 7 or 14 days. |
| D014848 |
| Vulvovaginitis |
| D014627 | Vaginitis |
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D014847 | Vulvitis |
| D014845 | Vulvar Diseases |
| D000091662 | Genital Diseases |
| D001424 | Bacterial Infections |
| D014245 | Trichomonas Infections |
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D001393 |
| Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |